# Haemostatix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haemostatix

- Industry: Biotechnology
- Headquarters: Nottingham, UK
- Website: www.haemostatix.com
- Total disclosed funding: $1.3M
- Latest round: Series C (Oct 1, 2012)
- Investors on record: 7

## About

Haemostatix Ltd. focuses on developing and commercializing innovative hemostatic products aimed at effectively managing bleeding disorders and enhancing surgical outcomes.Founded in 2003 and headquartered in Nottingham, UK, Haemostatix Ltd. specializes in creating advanced hemostatic solutions. The company was acquired by Ergomed PLC in May 2016 for an initial consideration of GBP 8 million, with a contingent consideration of GBP 20 million. Haemostatix has successfully completed 9 deals since its inception, with its latest deal occurring in May 2016.Haemostatix specializes in the development and commercialization of innovative hemostatic products designed to address a range of bleeding disorders and surgical needs. Their core product offerings include advanced topical hemostats and surgical adjuncts that promote rapid blood clotting during medical procedures. These products utilize proprietary formulations enhancing the body's natural coagulation processes, reducing surgical complications and improving patient outcomes. End users include hospitals, surgical centers, and healthcare professionals across North America, Europe, and Asia.In 2022, Haemostatix reported revenue of GBP 457,962.6, with an EBITDA of GBP -131,083.4 for the year 2023. The company generates revenue primarily through direct sales of its hemostatic products to healthcare providers, utilizing a straightforward supply chain model based on per-unit sales and bulk purchasing agreements, along with partnerships with distributors to expand market reach.Haemostatix is focused on launching new hemostatic products and expanding its market presence in regions such as North America and Asia by 2025. The recent funding from the Trade Sale, amounting to GBP 28 million, will support these initiatives, including the development of new products aimed at improving patient safety and procedural effectiveness.

## Funding rounds

- Series C, Oct 1, 2012, $1.3M — Albion Capital, Catapult Ventures Group, SPARK Ventures, NESTA Investments, Esperante Ventures, University of Leicester, The Lachesis Fund

## Investors

- Albion Capital — Series C
- Catapult Ventures Group (https://capitalatlas.ai/funds/catapult-ventures-group) — Series C
- SPARK Ventures — Series C
- NESTA Investments — Series C
- Esperante Ventures (https://capitalatlas.ai/funds/esperante-ventures) — Series C
- University of Leicester — Series C
- The Lachesis Fund (https://capitalatlas.ai/funds/the-lachesis-fund) — Series C